CapsiAtra (Dihydrocapsiate)

CapsiAtra (dihydrocapsiate) is a non-pungent capsaicinoid compound derived from sweet peppers that activates TRPV1 receptors to enhance thermogenesis. Clinical research indicates it may increase resting energy expenditure by approximately 50 kcal/day without causing gastrointestinal irritation.

Origin & History

CapsiAtra is a branded form of dihydrocapsiate (DHC), a non-pungent capsinoid naturally occurring in CH-19 Sweet chili peppers discovered in Japan. It is produced synthetically via enzymatic esterification of vanillyl alcohol and 8-methylnonanoic acid, yielding a ≥98% pure compound that provides capsaicin-like benefits without the burning sensation.

Historical & Cultural Context

Dihydrocapsiate was first isolated from CH-19 Sweet peppers by Yazawa et al. in 1989, with no documented traditional medicine use. Unlike capsaicin-containing peppers with extensive historical applications, capsinoids like DHC lack evidence of pre-modern use in traditional systems such as Ayurveda or TCM.

Health Benefits

• Increases resting energy expenditure by 50 kcal/day (based on one small RCT, n=12)
• Stimulates fat oxidation through TRPV1 receptor activation (mechanism-based evidence)
• Boosts basal metabolism without gastrointestinal irritation (limited clinical evidence)
• May support weight management efforts (preliminary evidence from one 4-week trial)
• Enhances thermogenesis without the pungency of capsaicin (mechanistic studies only)

How It Works

CapsiAtra activates transient receptor potential vanilloid 1 (TRPV1) channels in sympathetic nerve terminals, triggering norepinephrine release. This stimulates β3-adrenergic receptors in brown and white adipose tissue, activating uncoupling protein 1 (UCP1) to increase thermogenesis. Unlike capsaicin, dihydrocapsiate bypasses vanilloid receptor desensitization, providing sustained metabolic enhancement without tolerance development.

Scientific Research

Clinical evidence for dihydrocapsiate is limited to one small randomized, double-blind, placebo-controlled crossover trial (n=12) showing a 50 kcal/day increase in resting energy expenditure over 4 weeks (PMC2954444). While CapsiAtra marketing references over 50 capsinoid studies, specific dihydrocapsiate RCTs beyond this single trial are not available, and trial NCT00999297 lacks accessible details.

Clinical Summary

One small randomized controlled trial (n=12) demonstrated that CapsiAtra supplementation increased resting energy expenditure by 50 kcal/day compared to placebo. The study showed enhanced fat oxidation rates and improved substrate utilization during rest periods. However, evidence remains limited due to small sample size and lack of long-term weight loss data. Additional larger-scale trials are needed to confirm metabolic benefits and establish optimal dosing protocols.

Nutritional Profile

CapsiAtra is a standardized extract of Capsicum annuum (sweet pepper) providing ≥2% dihydrocapsiate (DCT), a non-pungent capsaicinoid analog. Dihydrocapsiate (chemical formula: C₁₈H₂₆O₄, MW ~306.4 g/mol) is an ester of vanillyl alcohol and 8-methylnonanoic acid, structurally related to capsaicin but lacking the amide bond responsible for pungency. Typical commercial doses range from 3–9 mg dihydrocapsiate per day, with 6 mg/day being the most commonly studied dose for thermogenic effects. The extract itself is virtually devoid of macronutrients (negligible protein, fat, carbohydrate, and fiber at supplemental doses). It contains no significant vitamins or minerals at effective dosing levels. Key bioactive compound: Dihydrocapsiate (≥2% of extract weight; ~2–6 mg per typical serving of 100–300 mg extract). Minor related capsinoids may include nordihydrocapsiate and homodihydrocapsiate at trace levels (<0.5%). Bioavailability notes: Dihydrocapsiate is rapidly hydrolyzed in the gastrointestinal tract and intestinal mucosa by lipase and esterase enzymes, yielding vanillyl alcohol and a fatty acid chain. Despite extensive first-pass hydrolysis (oral bioavailability of intact dihydrocapsiate is very low, estimated <1% reaching systemic circulation unchanged), the compound activates TRPV1 (transient receptor potential vanilloid 1) receptors locally in the gut mucosa and afferent sensory neurons before degradation, which is believed to mediate its thermogenic signaling via sympathetic nervous system activation. The metabolite vanillyl alcohol is rapidly conjugated (glucuronidation/sulfation) and excreted. Peak plasma metabolite levels occur within 15–40 minutes post-ingestion. The ester bond hydrolysis distinguishes its pharmacokinetics from capsaicin (which has an amide bond resistant to rapid GI hydrolysis), explaining the absence of oral/gastric burning sensation. Fat co-ingestion may modestly slow hydrolysis but clinical significance is unclear. No known drug-nutrient interactions at standard doses. Caloric contribution at supplemental doses is effectively zero (<1 kcal).

Preparation & Dosage

Clinically studied dose: 1 mg/day of pure dihydrocapsiate in capsules (diluted to 0.5% in refined rapeseed oil) for 4 weeks. CapsiAtra is marketed as a standardized extract with ≥98% purity, though specific dosing recommendations for commercial products are not established in clinical trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Green tea extract (EGCG), L-carnitine, Chromium picolinate, Forskolin, Cayenne pepper extract

Safety & Interactions

CapsiAtra appears well-tolerated with minimal reported side effects, unlike capsaicin which causes gastrointestinal irritation. No significant drug interactions have been documented, though theoretical interactions with thermogenic compounds or blood pressure medications warrant caution. Individuals with cardiovascular conditions should consult healthcare providers before use due to potential sympathetic nervous system activation. Safety during pregnancy and lactation has not been established.